Fate Therapeutics, Inc. (FATE)
| Market Cap | 5.47B |
| Revenue (ttm) | 48.01M |
| Net Income (ttm) | -212.02M |
| Shares Out | 94.33M |
| EPS (ttm) | -2.34 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,391,820 |
| Open | 58.91 |
| Previous Close | 59.00 |
| Day's Range | 57.17 - 59.77 |
| 52-Week Range | 42.64 - 121.16 |
| Beta | 1.73 |
| Analysts | Buy |
| Price Target | 108.79 (+87.1%) |
| Est. Earnings Date | Nov 4, 2021 |
About FATE
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors...
Financial Performance
In 2020, FATE's revenue was $31.43 million, an increase of 194.33% compared to the previous year's $10.68 million. Losses were -$173.39 million, 76.7% more than in 2019.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for FATE stock is "Buy." The 12-month stock price forecast is 108.79, which is an increase of 87.05% from the latest price.
News
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2021 Financial Results
SAN DIEGO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of pro...
Tentarix Biotherapeutics Emerges with $50 Million Series A
SAN DIEGO & VANCOUVER, British Columbia--(BUSINESS WIRE)--Biotechnology company Tentarix Biotherapeutics LP today announced a $50 million Series A investment co-led by Versant Ventures and Samsara BioCa...
3 Biotech Stocks to Watch Now
Biotech companies develop new medicines, vaccines, or medical devices. They use advanced technologies and medical science to do so.
Fate Therapeutics Announces Presentations at the Society for Immunotherapy of Cancer 2021 Annual Meeting
SAN DIEGO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for pa...
Recent Poor Results Have Made This Promising Cathie Wood Pick a Bargain
Positive news versus poor clinical trial results may determine the future of Fate Therapeutics.
Why Is Fate Therapeutics (FATE) Down 21% Since Last Earnings Report?
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock?
Fate Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for c...
Why Fate Therapeutics Stock Is Sliding Today
The positive results the company announced after the bell yesterday didn't meet some lofty expectations.
Fate Therapeutics' Stem Cell-Derived NK Lymphoma Candidate Casts Doubt Over Durability Of Response
Fate Therapeutics Inc (NASDAQ: FATE) revealed an early cut of Phase I data for its FT596 and FT516 programs for relapsed / refractory B-cell lymphoma. At the 2021 American Society of Clinical Oncology M...
Fate Therapeutics Announces Positive Interim Clinical Data from its FT596 and FT516 Off-the-shelf, iPSC-derived NK Ce...
10 of 14 Patients in FT596 Single-Dose Escalation Cohorts 2 and 3 Achieved Objective Response; 7 Patients Achieved Complete Response, including 2 of 3 Patients Treated with FT596 in Combination with Rit...
FATE Reports Wider-Than-Expected Q2 Loss, Beats on Revenues
FATE reports a wider loss on increased R&D expenses in the second quarter.
Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates
Fate Therapeutics (FATE) delivered earnings and revenue surprises of -11.54% and 89.70%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Fate Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Operational Progress
First Patient Treated for Relapsed / Refractory ALL in Landmark Phase 1 Clinical Trial of FT819, the First-ever iPSC-derived CAR T-cell Therapy; Off-the-Shelf Product Candidate Derived from Clonal Maste...
Cathie Wood's ARK Invest Buys Over 240,000 Shares of Fate Therapeutics
A couple of the ARK Invest exchange-traded funds run by ETF star Cathie Wood made a sizable purchase on Tuesday.
Fate Therapeutics Announces Treatment of First Patient in Landmark Phase 1 Clinical Trial of FT819, the First-ever iP...
Off-the-Shelf CAR T-cell Product Candidate Derived from Clonal Master iPSC Line with Novel CD19-specific 1XX CAR Integrated into TRAC Locus
Earnings Preview: Fate Therapeutics (FATE) Q2 Earnings Expected to Decline
Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top Biotech Stocks To Watch After Bristol Myers' Opdivo Sees Q2 Growth
Hot biotech stocks to watch right now as cancer treatments make headlines in 2021. The post Top Biotech Stocks To Watch After Bristol Myers' Opdivo Sees Q2 Growth appeared first on Penny Stocks to Buy, ...
Did You See What Cathie Wood Bought on Wednesday?
ARK Invest added to its stakes in DraftKings, Fate Therapeutics, and Zoom Video, all of which are trading well below their recent peaks.
Fate Therapeutics to Host Virtual Event Highlighting Interim Phase 1 Clinical Data from its Off-the-Shelf, iPSC-deriv...
SAN DIEGO, July 16, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for ca...
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2021 Financial Results
SAN DIEGO, July 15, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for ca...
Cathie Wood's ARK Invest Buys Over 530,000 Shares of Fate Therapeutics
One of the ARK Invest exchange-traded funds run by ETF star Cathie Wood made a sizable purchase on Wednesday.
Fate Therapeutics Appoints Mark Plavsic, DVM, PhD, RAC as Chief Technical Officer
SAN DIEGO, June 15, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for ca...
The Rally Likely To Continue For Fate Therapeutics After Positive Clinical Trials Data
The stock price of Fate Therapeutics, a biopharmaceuticals company focused on oncology and immunology treatments based on natural killer T-Cell programs, has seen a 9% rise over the last five trading da...
Fate Therapeutics Stock is Trading Higher on Positive B-Cell Lymphoma Data at ASCO21
Fate Therapeutics Inc (NASDAQ: FATE) has revealed some new data from an ongoing Phase 1 trial evaluating FT516 for patients with relapsed / refractory B-cell lymphoma. Data were presented at the 2021 Am...